Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.73 |
| ▸ | RXRA | P19793 | 2/20 | 0.68 |
| ▸ | RARG | P13631 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.58 |
| ▸ | PPARA | Q07869 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035192 | 0.88 | PPARG (0.73) | PPARGRXRARARGFFAR1PPARA | |
| SCHEMBL13850262 | 0.85 | PPARG (0.73) | PPARGRXRARARGFFAR1PPARA | |
| SCHEMBL13524842 | 0.85 | PPARG (0.73) | PPARGRXRARARGFFAR1PPARA | |
| SCHEMBL7507856 | 0.85 | PPARG (0.69) | PPARGRXRARARGFFAR1PPARA | |
| SCHEMBL13847858 | 0.85 | PPARG (0.69) | PPARGRXRARARGFFAR1PPARA | |
| SCHEMBL13847850 | 0.85 | PPARG (0.72) | PPARGRXRARARGFFAR1PPARA | |
| Rosiglitazone SCHEMBL5169 | 0.84 | PPARG (1.00) | PPARGRXRARARGFFAR1PPARA | |
| Rosiglitazone SCHEMBL7052472 | 0.84 | PPARG (1.00) | PPARGRXRARARGFFAR1PPARA | |
| Rosiglitazone SCHEMBL2355017 | 0.84 | PPARG (1.00) | PPARGRXRARARGFFAR1PPARA | |
| Rosiglitazone SCHEMBL29530259 | 0.84 | PPARG (1.00) | PPARGRXRARARGFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125358-A1 | Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation | SMITHKLINE BEECHAM P.L.C. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125358-A1 | Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation | TNNT2, FABP3, TNNI3 | PPARG 31/4885RXRA 975/4885RARG 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.